OpenResearchAlpha

Journal of Medical Internet Research · 11 Nov 2026

Imaging-Based AI for Predicting Pathological Complete Response in Esophageal Cancer After Neoadjuvant Therapy: Systematic Review and Meta-Analysis

Zhiwei Lih-index 0, Xin Gao, Jing Zhou, Lei Wang, Fuqiang Renh-index 0

0
Citations
no database records one yet
0
Citations in 2026
so far
0
Leading author's h-index
Zhiwei Li, in QAI's scholar index
78
References
works it cites, from open citation data

Citations by database

Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.

  • OpenCitations0
  • Crossref0
  • Europe PMC0

Citations per year

The current year is still counting.

  • 2026 so far0

Abstract

Abstract Background Imaging-based AI may help predict pathological complete response (pCR) after neoadjuvant therapy for esophageal cancer. However, an encouraging average diagnostic performance does not establish reliable performance across clinical settings or justify treatment decisions without further validation. Objective We aimed to assess the predictive performance of imaging-based AI across neoadjuvant strategies, distinguish internal from external validation, and examine limitations affecting interpretation. Methods PubMed, Embase, Web of Science, and the Cochrane Library were searched through August 7, 2026. Eligible English-language studies evaluated imaging-based AI against pathological assessment of pCR. PROBAST+AI (Prediction Model Risk of Bias Assessment Tool plus Artificial Intelligence) assessed study quality and risk of bias; GRADE (Grading of Recommendations Assessment, Development, and Evaluation) assessed certainty for sensitivity, specificity, and diagnostic odds ratio (DOR). Bivariate random-effects models synthesized validation groups separately. CIs described uncertainty in average performance, whereas 95% prediction intervals (PIs) described true performance in a similar new study. Results Thirty-three studies contributed 27 internal-validation datasets with 1891 patients and 16 external-validation datasets with 777 patients. Ten publications contributed to both groups. The sum was 2668 validation observations; the unique patient count across datasets and publications could not be verified. Internal sensitivity was 0.77 (95% CI 0.72‐0.81; PI 0.57‐0.89), specificity 0.82 (95% CI 0.78‐0.86; PI 0.60‐0.93); DOR, 15.49 (95% CI 11.16‐21.50); and area under the curve (AUC), 0.86 (95% CI 0.83‐0.89). External sensitivity was 0.73 (95% CI 0.61‐0.81; PI 0.34‐0.93), specificity 0.83 (95% CI 0.73‐0.90; PI 0.36‐0.98), DOR 12.93 (95% CI 7.25‐23.07), and AUC 0.84 (95% CI 0.79‐0.89). DOR PIs were 5.40‐44.44 and 2.40‐69.62, respectively. Thirty-two studies were conducted in China, and 12 had high validation risk of bias. All GRADE-assessed outcomes had very low certainty. Selecting the first eligible imaging model reported in each article instead of the highest-AUC model showed modest decreases in average performance across 16 internal and 10 external datasets; incomplete alternative-model reporting limited interpretation. Single study algorithm estimates were reported descriptively, without ranking algorithms or interpreting their CIs as evidence of between study consistency or generalizability. Conclusions By combining multiple neoadjuvant strategies and separating validation stages, this review extends earlier neoadjuvant chemoradiotherapy (NCRT)-focused syntheses and identifies priorities for further model evaluation. Imaging-based AI may support response assessment, but wide PIs, risk of bias, and very low evidence certainty preclude routine clinical adoption without prospective, geographically diverse validation. Future studies should evaluate prespecified models in independent populations, report clinically relevant decision thresholds, and assess calibration and patient outcomes. Until such evidence is available, these models should be considered investigational adjuncts to response assessment and should not independently guide organ preservation or omission of surgery after neoadjuvant treatment.

What the data shows

  • No database records a citation yet, as is usual for a paper this new.
  • Zhiwei Li has the highest h-index among the authors (0).

Graph

This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.

Citing paper shares an authorAuthor without a profileSize shows citations, or h-index for authors

Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.

Start with

Authors (5)

Each author's standing in QAI's scholar index: the works their ORCID iD is attached to, and for anyone whose ORCID record names a lab OpenResearch follows, their arXiv preprints matched by name and a shared co-author. Names are as printed on the paper.

ProfileMost-cited paper

Cited by 0 papers

Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.

0 shown
No citing papers for this filter.

References (78)

What it cites, from open citation data, with Crossref's record of each.

Sign in to see 58 more references

A free account opens the rest of the citing papers and references on every paper’s page.